These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. Oglesby A; Algazi AP; Daud AI Am J Clin Dermatol; 2019 Dec; 20(6):781-796. PubMed ID: 31228012 [TBL] [Abstract][Full Text] [Related]
24. Implantable Synthetic Immune Niche for Spatiotemporal Modulation of Tumor-Derived Immunosuppression and Systemic Antitumor Immunity: Postoperative Immunotherapy. Phuengkham H; Song C; Um SH; Lim YT Adv Mater; 2018 May; 30(18):e1706719. PubMed ID: 29572968 [TBL] [Abstract][Full Text] [Related]
25. Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy. Song Q; Yin Y; Shang L; Wu T; Zhang D; Kong M; Zhao Y; He Y; Tan S; Guo Y; Zhang Z Nano Lett; 2017 Oct; 17(10):6366-6375. PubMed ID: 28858519 [TBL] [Abstract][Full Text] [Related]
26. In situ thermal ablation of tumors in combination with nano-adjuvant and immune checkpoint blockade to inhibit cancer metastasis and recurrence. Han X; Wang R; Xu J; Chen Q; Liang C; Chen J; Zhao J; Chu J; Fan Q; Archibong E; Jiang L; Wang C; Liu Z Biomaterials; 2019 Dec; 224():119490. PubMed ID: 31542515 [TBL] [Abstract][Full Text] [Related]
27. Development of adaptive immune effector therapies in solid tumors. Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P; Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646 [TBL] [Abstract][Full Text] [Related]
28. Firing Up Cold Tumors. Cheng WC; Ho PC Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357 [TBL] [Abstract][Full Text] [Related]
29. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Wang G; Chow RD; Bai Z; Zhu L; Errami Y; Dai X; Dong MB; Ye L; Zhang X; Renauer PA; Park JJ; Shen L; Ye H; Fuchs CS; Chen S Nat Immunol; 2019 Nov; 20(11):1494-1505. PubMed ID: 31611701 [TBL] [Abstract][Full Text] [Related]
30. Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity. Ren L; Wan J; Li X; Yao J; Ma Y; Meng F; Zheng S; Han W; Wang H Nat Commun; 2024 Sep; 15(1):7664. PubMed ID: 39227567 [TBL] [Abstract][Full Text] [Related]
31. Bioengineered nanogels for cancer immunotherapy. Ma X; Li SJ; Liu Y; Zhang T; Xue P; Kang Y; Sun ZJ; Xu Z Chem Soc Rev; 2022 Jun; 51(12):5136-5174. PubMed ID: 35666131 [TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Wilky BA Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494 [TBL] [Abstract][Full Text] [Related]
33. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943 [TBL] [Abstract][Full Text] [Related]
34. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Kuai R; Yuan W; Son S; Nam J; Xu Y; Fan Y; Schwendeman A; Moon JJ Sci Adv; 2018 Apr; 4(4):eaao1736. PubMed ID: 29675465 [TBL] [Abstract][Full Text] [Related]
35. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. Rodallec A; Sicard G; Fanciullino R; Benzekry S; Lacarelle B; Milano G; Ciccolini J Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1139-1147. PubMed ID: 30354685 [TBL] [Abstract][Full Text] [Related]
36. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment. Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085 [TBL] [Abstract][Full Text] [Related]
37. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy. Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650 [TBL] [Abstract][Full Text] [Related]
38. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. Kwilas AR; Ardiani A; Donahue RN; Aftab DT; Hodge JW J Transl Med; 2014 Nov; 12():294. PubMed ID: 25388653 [TBL] [Abstract][Full Text] [Related]
39. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903 [TBL] [Abstract][Full Text] [Related]
40. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]